Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 4/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23951729 | 1.00 | TACR1 (0.55) | TACR1PDE4BRORCABL1DEGS1 | |
| SCHEMBL28932930 | 1.00 | TACR1 (0.55) | TACR1PDE4BRORCABL1DEGS1 | |
| SCHEMBL23923854 | 0.87 | ABL1 (0.48) | ABL1DEGS1GSK3BDYRK1ATRPV1 | |
| SCHEMBL23923853 | 0.87 | ABL1 (0.48) | ABL1DEGS1GSK3BDYRK1ATRPV1 | |
| SCHEMBL10165990 | 0.86 | GSK3B (0.52) | TACR1ABL1USP30GSK3BDYRK1A | |
| SCHEMBL23951809 | 0.83 | TACR1 (0.51) | TACR1PDE4BRORCTNFUSP30 | |
| SCHEMBL29900568 | 0.83 | TACR1 (0.51) | TACR1PDE4BRORCTNFUSP30 | |
| SCHEMBL23951495 | 0.82 | TACR1 (0.61) | TACR1PDE4BRORCABL1DEGS1 | |
| SCHEMBL23951349 | 0.81 | TACR1 (0.54) | TACR1PDE4BRORCUSP30USP7 | |
| SCHEMBL28932924 | 0.81 | TACR1 (0.54) | TACR1PDE4BRORCUSP30USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878514-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TACR1 3676/4885PDE4B 2677/4885RORC 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.